{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:42:36Z","timestamp":1769636556143,"version":"3.49.0"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T00:00:00Z","timestamp":1226275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>\n                    <jats:bold>Objective.\u2014<\/jats:bold>\n                    To evaluate the long\u2010term safety and tolerability of divalproex sodium extended\u2010release in the prophylaxis of migraine headaches in adolescents.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Background.\u2014<\/jats:bold>\n                    Divalproex sodium has been approved for migraine prophylaxis in adults. A previous double\u2010blind, placebo\u2010controlled study of the efficacy and safety of divalproex sodium extended\u2010release for prevention of migraine in adolescents was followed by the present long\u2010term extension trial, which was designed to collect additional safety and tolerability data.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.\u2014<\/jats:bold>\n                    This was a 12\u2010month, Phase 3, open\u2010label extension of a 3\u2010month, double\u2010blind, placebo\u2010controlled, multicenter study of adolescents aged 12 to 17 years with migraine headaches who had either completed the previous study or had discontinued because of lack of efficacy. Subjects from the previous trial who had experienced serious adverse events possibly or probably related to study drug were excluded. Divalproex sodium extended\u2010release 500\u2003mg daily was administered for 15 days then increased to 1000\u2003mg. Study visits were conducted at days 1 and 15 and months 1, 2, 3, 6, 9, and 12. Safety assessments included adverse event collection, laboratory testing, physical and neurological examinations, vital signs, and electrocardiograms, as well as reproductive endocrine analyses for postmenarchal female subjects. Efficacy was evaluated by sequential 4\u2010week migraine headache rates calculated from subjects' headache diaries.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.\u2014<\/jats:bold>\n                    A total of 112 subjects enrolled in the trial. The most common adverse events were weight gain (15%), nausea (14%), somnolence (12%), upper respiratory tract infection (11%), increased ammonia (8%), and sinusitis (8%). Five (4%) subjects experienced serious adverse events, and 15 (13%) subjects prematurely discontinued because of an adverse event. Increased ammonia levels were noted in some individuals, and the mean ammonia level for all subjects increased 19.2\u2003\n                    <jats:italic>\u00b5<\/jats:italic>\n                    <jats:sc>m<\/jats:sc>\n                    from baseline. No other clinically significant changes were observed in laboratory values, vital signs, or electrocardiograms. Improvement in mean and median 4\u2010week migraine headache rates occurred by the fourth month and lasted for the duration of the trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions.\u2014<\/jats:bold>\n                    In this long\u2010term open\u2010label extension study, the safety profile of divalproex sodium extended\u2010release in adolescents with migraine was consistent with that observed in the preceding 3\u2010month, double\u2010blind trial and in previous adult studies. Overall, divalproex sodium extended\u2010release was well\u2010tolerated in adolescents aged 12 to 17 years.\n                  <\/jats:p>","DOI":"10.1111\/j.1526-4610.2008.01299.x","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T14:09:33Z","timestamp":1226326173000},"page":"36-44","source":"Crossref","is-referenced-by-count":16,"title":["Safety and Tolerability of Divalproex Sodium Extended\u2010Release in the Prophylaxis of Migraine Headaches: Results of an Open\u2010Label Extension Trial in Adolescents"],"prefix":"10.1111","volume":"49","author":[{"given":"George","family":"Apostol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Pakalnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevieve A.","family":"Laforet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weining Z.","family":"Robieson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid M.","family":"Abi\u2010Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Saltarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738060210092201"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00631.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2004-2742"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000147332.41993.90"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100285"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002761"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1K049"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1702103.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540270077022"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1652"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2003.12.006"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2005.05.004"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2000.040008672.x"},{"key":"e_1_2_7_16_2","first-page":"32","article-title":"Low dose of sodium divalproate for the treatment of migraine","volume":"5","author":"Fragoso YD","year":"2003","journal-title":"MedGenMed"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.42404.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307380101601005"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2002.02186.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01081.x"},{"issue":"1","key":"e_1_2_7_21_2","first-page":"1","article-title":"The International classification of headache disorders","volume":"24","author":"Headache Classification Subcommittee of the International Headache Society","year":"2004","journal-title":"Cephalalgia"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/088307389701200709"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021918104127"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.50.3.275"},{"key":"e_1_2_7_25_2","volume-title":"Depakote ER (Divalproex Sodium Extended\u2010Release Tablets) Prescribing Information","author":"Abbott Laboratories","year":"2006"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.06.015"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2007.01.024"},{"key":"e_1_2_7_28_2","volume-title":"Tietz Clinical Guide To Laboratory Tests","author":"Wu A","year":"2006"},{"key":"e_1_2_7_29_2","unstructured":"United States Food and Drug Administration Center for Drug Evaluation and Research.Information for Healthcare Professionals: Suicidality and Antiepileptic Drugs. 1\/31\/2008;http:\/\/www.fda.gov\/cder\/drug\/InfoSheets\/HCP\/antiepilepticsHCP.htm. Accessed 2\/5\/2008."},{"key":"e_1_2_7_30_2","unstructured":"United States Food and Drug Administration Center for Drug Evaluation and Research.Statistical Review and Evaluation: Antiepileptic Drugs and Suicidality 5\/23\/2008;http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008\u20104372b1\u201001\u2010FDA.pdf. Accessed 7\/8\/08."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.66.66_suppl_3.S23"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000125745.60149.c6"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1526-4610.2008.01299.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1526-4610.2008.01299.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:46:00Z","timestamp":1762083960000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/j.1526-4610.2008.01299.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1111\/j.1526-4610.2008.01299.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1526-4610.2008.01299.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}